

Objective

Seeking \$6-10 million of equity financing for U.S. Sales and marketing expansion, TLC-2000 commercialization and FDA phase 1 development of patented photodynamic compounds activated by lasers that are able to destroy cancer, bacteria, and viruses.

The Company

Theralase Technologies Inc. designs, develops, manufactures and markets patented, super-pulsed laser technology used in a wide range of bio-stimulative and bio-destructive clinical applications.

September 2011 Fact Sheet

Ticker: Exchange	TLT: TSX Venture
Share Price (Sept. 7 th 2011) :	\$0.46
52 Week Range:	\$0.375 - \$0.820
Shares Outstanding:	40.4 million
Market Capitalization:	\$18.6 million

Value Driven Milestones

Q2 '11
Aggressively expand into the US marketplace by hiring experienced medical equipment sales personnel.

Q3 '11
Submit FDA, Health Canada and CSA approvals for the TLC-2000 Biofeedback Medical Laser.

Q4 '11
Publication of the initial results utilizing PDCs to target cancer cells.

Q1 '12
TLC-2000 Therapeutic Biofeedback Medical Laser launched to all practitioners.

Q1 '12
Companion animal oncology testing at Princess Margaret Hospital

Q3 '12
Developing commercialization path for PDC technology

Large U.S. Market Opportunity

More than **56 million** patients suffer from chronic pain and chronic wounds in the U.S. and the market opportunity is estimated at over **\$50 billion** annually.

The public's desire for high efficacy, drug-free treatments in an aging population is creating a significant opportunity for Theralase.

Proven Technology

- Cold lasers are clinically proven to be the fastest and most effective method of treating pain and healing wounds.
- 2,500 clinical studies worldwide attest to the clinical efficacy of cold lasers.
- Cold lasers have no side effects, are non-invasive and provide drug-free treatment.

Growth Strategy

TLC 1000

Q2'11 Theralase is aggressively expanding into the U.S. markets and has hired a dedicated sales team to focus on the five largest U.S. states: New York, Florida, Texas, California and Illinois.

TLC 2000

Q1'12 Theralase will launch the new biofeedback laser system using a recurring revenue model and will provide upgrade incentives to existing TLC-1000 customers.

TLC-3000

Theralase will continue R&D in combining patented Photodynamic Compounds with the company's patented laser technology to enter the cancer, bacteria, and virus destruction markets.



Key Products

TLC-1000 Laser Treatment Patent Pending

Target Audience: Physicians, Physiotherapists, Chiropractors and Athletic Trainers

Endorsed by: Professional Sports teams including the Toronto Blue Jays, Montreal Canadians and Washington Wizards.

Key Benefits:


1. TLC-1000 super-pulsed technology generates the highest peak power of all Class 3 cold lasers for the greatest depth of penetration;
2. Targets three cellular healing pathways; ATP for energizing cells, iNOS for elimination of inflammation and bilipid pathway for pain removal.
3. Offers more pre-programmed treatment protocols than competitive cold lasers.
4. Can be used unattended allowing practitioners to treat multiple patients simultaneously.

TLC-2000 Laser Treatment Patented Technology


- Theralase will commence selling its next generation therapeutic laser, the TLC-2000, in Q1 2012.
- The patented TLC-2000 laser has the ability to more precisely treat pain and wounds by delivering exact energy doses to precise tissue locations and has a learning feature to record the most effective treatments.
- Theralase has commissioned clinical studies by the University of Buffalo to demonstrate the efficacy of the new biofeedback technology.

TLC-3000 Laser Treatment Patented Technology

- Theralase is researching and developing patented photodynamic compounds (PDCs) with patented laser technology to destroy cancers, bacteria, and viruses.
- The publication of the initial results on using PDCs to destroy cancer cells is expected in the latter half of 2011
- Commencement of the TLC-3000 laser system to activate the compounds is scheduled to commence in the first half of 2012.



TLC-2000 Biofeedback technology accurately determines laser fluence rates at tissue depth.



Cells possessing PDCs awaiting destruction by a Theralase laser.

Key Financials

Subsequent to the Company's 2010 year-end, Theralase completed an oversubscribed private placement on January 7, 2011 for gross proceeds of \$737,500.

CDN\$	2007A	2008A	2009A	2010A
Revenues	1,559,850	2,168,411	2,359,855	2,040,537
Net income/(loss)	(1,113,373)	(1,111,675)	(241,578)	(1,199,726)
R&D expenses	222,414	226,748	164,184	547,987
Net cash	507,969	49,134	1,187,104	174,401
Working capital	839,721	158,426	1,405,162	424,909

Investment Highlights

- Proprietary laser technology that effectively treats pain and heals wounds without the side effects of drugs
- Growth strategy to expand into the U.S. market, introduce a recurring revenue model and launch a consumer laser system
- R&D into combining PDCs with laser technology to destroy cancers, bacteria, and viruses.

Management Team

Roger Dumoulin-White, P.Eng, President and CEO

Kristina Hachey, CGA, CFO

Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer

Dr. Rhonda Mostyn DC, Clinic Director

Board of Directors

S. Donald Moore, Chairman

Roger J. Dumoulin-White, President and CEO

Randy Bruder

John A. Murphy

Richard Kostoff

Medical and Scientific Advisors

Dr. James R. Andrews, Chairman and Medical Director, American Sports Medicine Institute (ASMI)

Dr. Lyle Cain, American Academy of Orthopedic Surgeons (AAOS), International Cartilage Repair Society (ICRS) and ASMI

Dr. Jeffrey Dugas, American Orthopedic Society for Sport Medicine, AAOS, ICRS and ASMI

Kevin Wilk, PhD, DPT, Champion Sports Medicine, American Physical Therapy Association

Lanier Johnson, Executive Director, American Sports Medicine Institute, developer of the Sports Medicine Program for the PGA Tour

Investor Relations

Greg Bewsh

Investor Relations

Tel: 416.447.8455 X.262

Cell: 647.462.2229

gbewsh@theralase.com

ir@theralase.com

Contact

Theralase Technologies Inc.

29 Gervais Drive, Suite 102

Toronto, Ontario, M3C 1Y9

Tel: 1.866.843.5273

Fax: 416.447.3020

www.theralase.com